Hepatic failure in a patient taking rosiglitazone

Annals of Internal Medicine

Volumn 132, Issue 2, 2000, Pages 118-121

  Forman, Lisa M ^a   Simmons, David A ^a   Diamond, Robert H ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ROSIGLITAZONE;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; DIABETES MELLITUS; DRUG MECHANISM; DRUG METABOLISM; HUMAN; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; MALE; PRIORITY JOURNAL;

EID: 0033984428     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-132-2-200001180-00005     Document Type: Article

References (17)

1. Henry RR. Thiazolidinediones. Endocrinol Metab Clin North Am. 1997;26: 553-73.
2. Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med. 1998;129:36-8.
3. Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ, et al. Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med. 1998;129:38-41.
4. Shibuya A, Watanabe M, Fujita Y, Saigenji K, Kuwao S, Takahashi H, et al. An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care. 1998;12:2140-3.
5. Vella A, deGroen PC, Dinneen SF. Fatal hepatotoxicity associated with troglitazone [Letter] Ann Intern Med. 1998;129:1080.
6. Herrine SK, Choudhary SC. Severe hepatotoxicity associated with troglitazone [Letter]. Ann Intern Med. 1999;130:163-4.
7. Plosker GL, Faulds D. Troglitazone. a review of its use in the management of type 2 diabetes melitus. Drugs. 1999;57:409-38.
8. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone [Letter]. N Engl J Med 1998;338:916-7.
9. Spencer CM, Markham A. Troglitazone. Drugs. 1997;54:89-101.
10. Balfour JA, Plosker GL. Rosiglitazone. Drugs 1999;57:921-30.
11. Prescribing information contained in the manufacturer's insert for Avandia. Philadelphia: SmithKline Beecham; May 1999.
12. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270:12953-6.
13. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45:1661-9.
14. Salzman A, Patel J. Rosiglitazone is not associated with hepatotoxicity [Abstract]. Diabetes. 1999;48:A63.
15. Elcock FJ, Lyon JJ, Hitchcock J, Morgan DG, Bertram TA, Bugelski PJ. Toxicity of troglitazone in cultured rat hepatocytes [Abstract]. Diabetes. 1999; 48:A95.
16. Gibson PR, Dudley FJ. Ischemic hepatitis: clinical features, diagnosis and prognoss. Aust N Z J Med. 1984;14:822-5.
17. Fuchs S, Bogomolskli-Yaholom V, Paltiel O, Ackerman Z. Ischemic hepatitis. J Clin Gastroenterol. 1998;26:183-6.